½¨Òé: ¼ûµÚ8.6Õ½Ú
ÒÀ²»Í¬Çé¿ö¶ø¶¨¡£µäÐ͵Ä×ö·¨ÊÇ£¬¹«Ë¾ÊµÊ©Ä¿²â¼ì²â£¬¸ù¾ÝÒªÇóÈ¡ÁÜÏ´Ñù±¾¡£
Çå½àÑéÖ¤Íê³Éºó£¬Ò»ÖÖÓÐЧµÄ£¬¿ÆÑ§µÄ£¬³É±¾µÍµÄ¼à¿ØÇåÏ´µÄÓÐЧÐԵķ½·¨ÈçÏÂËùʾ£º 1.)Ä¿²âÉ豸µÄÇå½à¶È¡£Ö»ÓÐÄ¿²â½á¹ûÂúÒâºó£¬²ÅÄܽøÐÐÏÂÒ»²½¡£ 2.)È¡ÁÜÏ´ºÍ/»ò²ÁÊÃÑùÆ·£¨Í¨³£ÒªÇóȡһ¹«ÉýµÄÁÜÏ´ÒºÌ壩¡£
3.)ʹÓÃÐýתÕô·¢ÒÇ£¬½«ÉÕÆ¿ÖеÄ500mlÑùÆ·Õô¸É£¬²â¸ÉÔï²ÐÁô¡£Õâ¸ö¼ìÑé·½·¨²»µ«¸²¸ÇÎÞ»úÑΣ¬ÒÑÖª»òδ֪Óлú²úÆ·Ò²²â¶¨×ܵIJÐÁôÁ¿¡££¨¶ÔÓÚºæ¸ÉÉ豸£¬ÕâÏî¼ì²â¿ÉÒÔºöÂÔ¡£ÒòΪÕâÖÖÇé¿öÏ£¬API»òÖмäÌåµÄ´¿¶È±È½Ï¸ß£¬Ò»°ãûÓи±²úÆ·£¬½µ½âÎïµÈÉú³É¡££© 4.)Èç¹û½á¹û·ûºÏ¹æ¸ñ±ê×¼£¬½øÐÐÌØ¶¨µÄ(É«Æ×·ÖÎö)¼¼Êõ¡£¿ªÊ¼-±¡²ãÉ«Æ×TLCÏ޶ȲâÊÔ(Á®¼Û²¢¿ìËÙÑéÖ¤£¬¿í¼ì²â·¶Î§-×ÏÍâUV£¬ÒÔ¼°¾ßÌåµÄÑÜÉú-Èç¹ûÕâЩ¼¼Êõ×éºÏ£¬¶ÔÓÚDZÔÚ´æÔÚÓÚÑù±¾Öв»Í¬µÄÔÓÖÊ£¬·½·¨ÊǷdz£×¨ÊôµÄ¡£Ó¦ÓÃ2¸öÑùÆ·£º×îºóÁÜÏ´Òº(²é¿´ËùÓÐDZÔÚ²ÐÁô)£¬ÁÜÏ´ÒºÌå(ѰÕÒ²ÐÁô)£¬ÒÔ¼°¶þ¸ö±ê×¼£ºÆäÒ»ÔÚÒѾ½ÓÊÜÏ޶ȵÄŨ¶ÈÉϼì²é²ÐÁô²úÆ·£¬ÒÔ¼°±ê×¼µÄ1:2Ï¡ÊÍ¡£Èç¹ûÔÚÁÜÏ´ÒºÖÐÖ÷°ßµã±È±ê׼ǿ¶ÈµÍ£¬É豸ÊǸɾ»µÄ¡£µÚ¶þ¸ö±ê×¼ÊÇÓÃÀ´¼ì²âÈ·ÈÏ¡£
5.) Èç¹ûTLC²»ÊÇÊʵ±µÄ¼¼Êõ£¬×ª»»³ÉHPLC»òGC¡£ ÎÊÌâ 4:ÔÚÇå½àÑéÖ¤ÖУ¬ÐèÒª¹Ø×¢ÄÄЩ¹Ø¼ü²ÎÊý£¿ ½¨Òé: Òª¸üÏêϸÇë¼ûµÚ8.2Õ½Ú
ÖØÒªµÄÊÇ£¬½áºÏÐèÒªÇå³ýµÄ²úÆ·²ÐÁô£¬Çå½àÊÔ¼ÁºÍÇå½à¼¼Êõ£¬ÏêϸÆÀ¼ÛÉ豸µÄÉè¼Æ¡£Ò²¿ÉÒÔ°üÀ¨Çå½à·½·¨µÄ²¨¶¯ÐÔºÍÔÙÏÖÐÔ¡£ ÎÊÌâ 5: Çå½à³ÌÐòµÄÑéÖ¤ÐèÒªÔËÐжàÉÙ´ÎÇå½à£¿ ½¨Ò飺²Î¿¼µÚ9.0½Ú¡£
ÑéÖ¤ÏîĿһ°ã°üÀ¨Èý´Î³É¹¦µÄÁ¬ÐøµÄÖØ¸´¡£È»¶ø£¬¹«Ë¾Ó¦¸Ã·Ö±ðÆÀ¹ÀÿÖÖÇé¿ö¡£ ÎÊÌâ 6: ÔÚ·ÖÎö½á¹ûÏÔʾÊÇÉ豸Çå½àµÄ֮ǰ£¬ÊÇ·ñ¿ÉÒÔ¼ÌÐøÊ¹ÓÃÒª±»ÑéÖ¤µÄÇå½à³ÌÐò£¿ ½¨Ò飺ҩÕþµ±¾Ö²»½ÓÊÜÕâÑùµÄ·½Ê½¡£
ÎÊÌâ7: ¹«Ë¾ÊÇ·ñÐèÒªÑéÖ¤Çå½àǰµÄÔàÉ豸ÔÊÐí±£³ÖµÄ×ʱ¼ä£¿
½¨Òé:¹«Ë¾Ó¦¸ÃÓÐSOP¹æ¶¨£¬Éú²ú½áÊøºóÓ¦Á¢¼´Ö´ÐÐÇå½à¡£ÕâÖÖÌØ¶¨Çé¿öÓ¦¸Ã¾¹ýÑéÖ¤¡£È»¶ø£¬Èç¹ûÓÉÓÚijÖÖÔÒò£¬²»ÄÜÁ¢¼´Ö´ÐÐÇå½à£¬¹«Ë¾Ó¦¸Ã¿¼ÂÇʱ¼ä³¤¶Ì¶ÔÉ豸ÉϳÁµíµÄÎïÁϵÄÓ°Ïì¡£Ò²¿ÉÄÜ¡°·Ö×顱»ò¡°·ÖÀࡱ²úÆ·£¬²¢ÑéÖ¤×Çé¿ö¡£ ÎÊÌâ8:¹«Ë¾ÊÇ·ñÓбØÒªÑéÖ¤É豸Á´Çå½àºóµ½Ê¹ÓÃǰµÄ×î´ó¼ä¸ôʱ¼ä£¿
½¨Òé:¹«Ë¾Ó¦¸ÃÓÐSOP±£Ö¤É豸Á´ÔÚÇåÏ´ºóµÃµ½³ä·Ö±£»¤£¬²»ÊÜÈκÎÎÛȾ£¬Èç±£Ö¤Éè±¸È«Ãæ¸²¸Ç£¬·À³¾µÈ¡£
Èç¹û¹«Ë¾ÈÏΪ£¬É豸Çå½àºóÓб»ÎÛȾµÄ·çÏÕ£¬ÑéÖ¤Òª¿¼ÂÇÕâЩ·çÏÕ¡£ ÎÊÌâ 9: Èç¹ûÉ豸²»±»¾³£Ê¹Óã¬ÊÇ·ñÓбØÒª½¨Á¢Çå½àµÄʱ¼ä·¶Î§£¿
µÚ38Ò³/¹²43Ò³
½¨Òé: Çë²Î¿¼¶ÔÎÊÌâ8µÄ½¨Òé¡£
ÎÊÌâ10: Ä©´ÎÓÃË®ÁÜÏ´ºó£¬ÔÊÐíµÄ×ÏÐÅZʱ¼äΪ¶àÉÙ£¿
½¨Òé:É豸Çå½àºó£¬É豸²»ÄÜ´øË®·ÅÅZ¡£ÒòΪÇå½à³ÌÐòµÄ×îºóÒ»²½°üÀ¨ÓÃÈܼÁºæ¸É»òµªÆø³åÏ´£¬Òò´ËÒª±£Ö¤²»ÄÜÓÐÈÃ΢ÉúÎï×ÌÉúµÄ»ú»á¡£
ÎÊÌâ11:ÊÇ·ñ¿ÉÄÜÓÉÓÚÉè±¸Ëæ×Åʱ¼ä¹ýÈ¥¶ø¿ÉÄÜ·¢Éú±ä»µ£¬Òò´ËÔÀ´µÄµÄÑéÖ¤½á¹û¾ÍÎÞЧÁË£¿
½¨Òé: ÖÆÔì/»¯Ñ§ÐÐÒµÉ豸µÄ²ÄÁϵıê×¼ºÜ¸ß¡£È»¶ø£¬Ó¦¸ÃÆÀ¹ÀʹÓõÄÉ豸²ÄÁϵÄÄÍÓÃÐÔ¡£Ó¦¸Ã¿¼ÂǶÔÇå½àÓÐÓ°ÏìµÄÈκÎÒòËØºÍÉ豸±íÃæ´Ö²ÚµÄ¿ÉÄÜÐÔ¡£
ÔÚÑéÖ¤ºó£¬×÷ΪÕâ¸ö¹ý³ÌµÄÒ»²¿·Ý£¬¹«Ë¾Ó¦µ±Ê¹ÓÃÈ·ÈÏ·½·¨¶Ô·ÖÎöµÃµ½Êý¾Ý½øÐÐ¼à¿Ø¡£ ÎÊÌâ 12: Èç¹û¹«Ë¾ÑéÖ¤¹ý×Çé¿ö£¨·Ö×é»ò·ÖÀࣩ£¬ÊÇ·ñÓбØÒªÑéÖ¤¡°ÉԺá±µÄ×Çé¿ö£¿
½¨Òé:ÔÚ¸ø²úÆ··ÖÀàºÍÈ·¶¨ÑéÖ¤µÄ×Çé¿öʱ£¬¹«Ë¾Ó¦¸ÃÈ·¶¨ÐèÑéÖ¤µÄ×Çé¿öÊÇ·ñÊʺÏÈÕ³£Éú²ú¡£ÓÉÓÚ²Ù×÷ÔÒò£¬¶ÔÓÚijЩ²úÆ·£¬ÑéÖ¤Ò»¸öÒªÇó¡°ÉÔ¿í¡±µÄÇå½àÑéÖ¤¿ÉÄܸüÓÐÒæ´¦¡£
ÎÊÌâ 13:¶ÔÓÚûÓнµ½â²úÎïµÄרÓóµ¼ä£¬ÊÇ·ñÐèÒªÑéÖ¤£¿ ½¨Òé: ¼ûµÚ7.0Õ½Ú
¹«Ë¾Ó¦µ±µ¥¶À¿¼ÂÇÿһÖÖÇé¿ö²¢ÑéÖ¤ÊÇ·ñ´æÔÚDZÔÚÎÛȾ¡£ÔÚÉÏÊöµÄÇé¿öÏ£¬Æä¿ÉÄܲ»ÐèÒª¡£È»¶ø£¬Ó¦µ±¿¼ÂÇÈ«ÃæÇå½àǰµÄÔËÐдÎÊý¡£ ÎÊÌâ 14:ÊÇ·ñÇå½àÑéÖ¤Ó¦µ±×÷Ϊ¿ª·¢ÏîÄ¿µÄÒ»¸ö²¿·Ý£¿
½¨Òé: ICHûÓÐÒªÇóÔÚ¿ª·¢½×¶ÎʵʩÇå½àÑéÖ¤£¬µ«Ó¦µ±¿¼ÂÇÏÂÁÐÎÊÌ⣺
ÔÚ¿ª·¢²úƷʹÓÃÉÌÒµÖÆÔìÓÃÉ豸ºó¾¹ýÇå½à£¬ÔÚÖØÐÂʹÓÃǰǡµ±ºËʵÉ豸µÄÇå½à¶ÈÊDZØÒªµÄ¡£
µ±²úÆ·±ä³ÉÓÐÉÌÒµ¼Ûֵʱ£¬²úÆ·Çå½à³ÌÐò¿ª·¢Ó¦µ±ÔÚ¿ª·¢½×¶Î½øÐÐÑéÖ¤¡£ ÎÊÌâ 15: ÔÚÑéÖ¤³ÌÐòÖÐÊÇ·ñÓбØÒª°üÀ¨Î¢ÉúÎï²âÊÔ/Íâ¹Û£¿ ½¨Òé: ²Î¿¼µÚ8.1½Ú¡£
Êǵġ£Èç¹ûºóÐø²úÆ·ÐèÒªÓÐÒ»¸öµÍµÄ΢ÉúÎï¸ºÔØ£¬Í¬ÑùҲȡ¾öÓÚËùʹÓõÄÇå½à¼Á£¬Èç¹ûºóÐø²úÆ·ÓÐÈκεÄ΢ÉúÎïÎÛȾµÄ·çÏÕ(ÀýÈ磬Èç¹ûË®ÓÃÓÚ×îºóµÄÇå½à)¡£
ÎÊÌâ 16: ÔÚÇå½àÑéÖ¤Ñо¿ÖÐÓ¦µ±Ê¹ÓÃÄÄÖÖ·ÖÎö·½·¨(ÊÇ·ñ½ö½ö¸ßЧҺÏàÉ«Æ×²âÊÔ¿ÉÒÔ½ÓÊÜ?)£¬ÒÔ¼°ÕâЩ·½·¨µÄÑéÖ¤³Ì¶È¶à´ó£¿
½¨Òé: Ref. Section 7.0 of this ¡°Guidance on Aspects Document¡± Æä½á¹û±ÈÑéÖ¤ÒªÇóÒªËÉ¡£(ÔÚICH-Q2AÓëQ2BÖÐÃèÊö)¡£
È»¶ø£¬Èç¹û¹«Ë¾¾ö¶¨ÑéÖ¤·ÖÎö·½·¨£¬²â¶¨ÔÚijЩ·¶Î§²ÐÁôµÄÊÊÓÃÐÔ (ÀýÈ磬˥¼õÇúÏߣ¬
µÚ39Ò³/¹²43Ò³
ÈκÎÊʺÏÓÚÔ¤ÆÚʹÓõķÖÎö·½·¨¶¼¿ÉÒÔʹÓá£ÔÚÇå½àÑéÖ¤Ñо¿ÖУ¬Ò»°ã½øÐÐÏ޶ȲâÊÔ£¬
À´Ö¤Ã÷ÔÚÔÚ¼Ó¹¤¹ý³ÌÖÐÓÃÓÉÿ¸öÇå½à²½ÖèËù×é³ÉµÄ¹æ¶¨Çå½à³ÌÐò½øÐеÄÇå½àÊdzɹ¦µÄ)£¬Í¬Ê±ÑéÖ¤ÒªÇóÒ²±È½ÏËÉ£¬ÀýÈ磬ҪÇóµÄÏßÐÔ¶ÈÓë׼ȷÐÔ¿ÉÒÔ½¨Á¢ÔÚµäÐ͵ÄÔÁÏÒ©·ÅÐвâÊÔ·½·¨µÄÑéÖ¤±È½ÏÉÏ¡£
ÎÊÌâ 17: ÊÇ·ñÐèÒªÔÚ²ÁÊÃÑùÆ·ºÍÁÜÏ´ÑùÆ·±»Åú×¼Ö®ºó£¬²ÅÄÜʹÓÃÉ豸Éú²ú£¿
ÔÚÇå½à¼ìÑéÑо¿ÆÚ¼ä£¬½¨ÒéµÈËùÓмƻ®µÄ¼ì²âÍê³ÉÖ®ºó£¬ÔÙ·ÅÐÐÉ豸ÓÃÓÚ½øÒ»²½Ê¹Óã¨Èç¹û¼ì²âʧ°Ü£¬ÓÐÄÜÁ¦Ö´Ðе÷²é£©¡£ÈÕ³£²Ù×÷ÖУ¨ÑéÖ¤Íê³Éºó£©£¬É豸µÄ·ÅÐÐÈ¡¾öÓÚ¼ì²âµÄ½á¹û£¨ºËʵ£¬¼ì²âµÄ¼à¿Ø×´Ì¬£©¡£¹«Ë¾ÄÚ²¿Ó¦¸Ã¶¨ÒåʹÓÃδ·ÅÐÐÉ豸µÄÔðÈκÍÌõ¼þ¡£
10.0 References ²Î¿¼ÊéÄ¿
Bracketing and Worst Case Rating ·ÖÀàºÍ×Çé¿öÆÀ¹À
1. USP 24, The United States Pharmacopoeia, United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852.
2. Casarett and Doull; .Toxicology - The Basic Science of Poisons.; Macmillan Publishing Co, Inc. New York, Ed.2; 1980.
3. William E. Hall, Ph.D., Hall & Associates, Validation of Cleaning Processes for Bulk Pharmaceutical Chemical Processes, Journal of Validation Technology. Determination of the Amount of Residue ²ÐÁôÁ¿È·¶¨
1. PIC PH I/96, in .Pharm. Ind. 58, Nr. 4 (1996); Draft API GMP Guide, PIC, Geneva September .97; Guide to Inspections Validation of Cleaning Processes, FDA, 93; Draft Guidance for Industry Manufacturing, Processing, or Holding API, FDA, April 98.
2. Validation of Analytical Procedures: Q2A, Definitions and Terminology, ICH, October 1994; Q2B, Methodology, ICH, November 1996. Validation Questions ÑéÖ¤ÎÊÌâ
1. Cleaning Validation in Active Pharmaceutical Ingredient Manufacturing Plants, CEFIC-APIC, September 6, 1999.
11.0 Glossary ÊõÓï Ai
Area for the tested piece of equipment # i. Ëù¼ì²âµÄµÚiºÅÉ豸²¿¼þÃæ»ý¡£
CO
True (measured) total quantity of substance (possible carryover) on the
µÚ40Ò³/¹²43Ò³
CONC
LD50
LOD
LOQ
mi
MACO
MACOppm
cleaned surface in contact with the product, calculated from results of swab tests.
ÓɲÁÊüì²â¼ÆËã³öµÄ£¬½à¾»µÄ¡¢Óë²úÆ·½Ó´¥µÄÉ豸±íÃæÉÏ£¬Ä³ÖÖÎïÖÊ£¨¿ÉÄÜ´øÈëµÄ£©µÄÕæÊµ£¨¾¹ý²âÁ¿£©×ÜÊýÁ¿¡£
Concentration (kg/kg or ppm) of ¡°previous¡± substance in the next batch. Based on MACO calculated from therapeutic doses and/or tox data. ¡°Ç°¡±ÎïÖÊÔÚºóÐøÅú´ÎÖеÄŨ¶È(kg/kg»òppm)¡£ÓÉÖÎÁƼÁÁ¿ºÍ/»ò¶¾ÀíÊý¾Ý¼ÆËã³ö×î´óÔÊÐí´øÈëÁ¿£¨MACO£©£¬È»ºó¼ÆËã³öÎÛȾÎïÖʵĿɽÓÊÜŨ¶È
Lethal Dose 50 in g/kg animal. The identification of the animal (mouse, rat etc.) and the way of entry (IV, oral etc.) is important.
ÒÔg/kg¼ÆÁ¿µÄ¶¯ÎïÖÁËÀÁ¿50¡£ÖØÒªµÄÊǶ¯Îï±æ±ð(´óÊó¡¢Ð¡ÊóµÈ)ºÍ¸øÒ©·½Ê½(¾²Âö¡¢¿Ú·þµÈ)¡£
Limit of detection. ×îС¼ì²âÏÞ¶È¡£
Limit of quantification. ×îС¶¨Á¿ÏÞ¶È¡£
Quantity, in ?g/dm2, for each swab per area of swabbed surface (normally 1 dm2)
µ¥Î»²ÁÊÃÃæ»ýÄÚµÄÒ»´Î²ÁÊõÄÊýÁ¿£¬ÒÔ?g/dm2 ¼Æ¡£
Maximum Allowable Carryover: acceptable transferred amount from the investigated product (¡°previous¡±)
×î´óÔÊÐí´øÈëÁ¿£ºÑéÖ¤Ñо¿µÄ²úÆ·£¨¡°Ç°¡±ÎïÖÊ£©µÄ¿É½ÓÊÜ×ªÒÆÁ¿
Maximum Allowable Carryover: acceptable transferred amount from the investigated product (¡°previous¡±). Calculated from general ppm limit.
µÚ41Ò³/¹²43Ò³
Ïà¹ØÍÆ¼ö£º